200 related articles for article (PubMed ID: 27511886)
1. Associations of the CYP3A5*3 and CYP3A4*1G polymorphisms with the pharmacokinetics of oral midazolam and the urinary 6β-hydroxycortisol/cortisol ratio as markers of CYP3A activity in healthy male Chinese.
Chan SW; Xiao Y; Hu M; Yin OQ; Chu TT; Fok BS; Lee VH; Tomlinson B
J Clin Pharm Ther; 2016 Oct; 41(5):552-8. PubMed ID: 27511886
[TBL] [Abstract][Full Text] [Related]
2. Evaluation of CYP3A activity in humans using three different parameters based on endogenous cortisol metabolism.
Luo X; Li XM; Hu ZY; Cheng ZN
Acta Pharmacol Sin; 2009 Sep; 30(9):1323-9. PubMed ID: 19701237
[TBL] [Abstract][Full Text] [Related]
3. The variability of liver graft function and urinary 6beta-hydroxycortisol to cortisol ratio during liver regeneration in liver transplant recipients.
Kishino S; Ogawa M; Takekuma Y; Sugawara M; Shimamura T; Furukawa H; Todo S; Miyazaki K
Clin Transplant; 2004 Apr; 18(2):124-9. PubMed ID: 15016124
[TBL] [Abstract][Full Text] [Related]
4. Poor correlation between 6beta-hydroxycortisol:cortisol molar ratios and midazolam clearance as measure of hepatic CYP3A activity.
Chen YC; Gotzkowsky SK; Nafziger AN; Kulawy RW; Rocci ML; Bertino JS; Kashuba AD
Br J Clin Pharmacol; 2006 Aug; 62(2):187-95. PubMed ID: 16842393
[TBL] [Abstract][Full Text] [Related]
5. Increase in urinary excretion of 6beta-hydroxycortisol in common marmosets as a marker of hepatic CYP3A induction.
Totsuka S; Watanabe T; Koyanagi F; Tanaka K; Yasuda M; Manabe S
Arch Toxicol; 1999; 73(4-5):203-7. PubMed ID: 10463384
[TBL] [Abstract][Full Text] [Related]
6. Plasma 6β-hydroxycortisol to cortisol ratio as a less invasive cytochrome P450 3A phenotyping method.
Hirano R; Yokokawa A; Furihata T; Shibasaki H
Br J Clin Pharmacol; 2024 Apr; 90(4):1016-1026. PubMed ID: 38102865
[TBL] [Abstract][Full Text] [Related]
7. Urinary 6β-Hydroxycortisol/Cortisol Ratio Most Highly Correlates With Midazolam Clearance Under Hepatic CYP3A Inhibition and Induction in Females: A Pharmacometabolomics Approach.
Shin KH; Ahn LY; Choi MH; Moon JY; Lee J; Jang IJ; Yu KS; Cho JY
AAPS J; 2016 Sep; 18(5):1254-1261. PubMed ID: 27317471
[TBL] [Abstract][Full Text] [Related]
8. Effect of the fluoroquinolone antibacterial agent DX-619 on the apparent formation and renal clearances of 6β-hydroxycortisol, an endogenous probe for CYP3A4 inhibition, in healthy subjects.
Imamura Y; Murayama N; Okudaira N; Kurihara A; Inoue K; Yuasa H; Izumi T; Kusuhara H; Sugiyama Y
Pharm Res; 2013 Feb; 30(2):447-57. PubMed ID: 23073666
[TBL] [Abstract][Full Text] [Related]
9. Association of ABCB1, CYP3A4*18B and CYP3A5*3 genotypes with the pharmacokinetics of tacrolimus in healthy Chinese subjects: a population pharmacokinetic analysis.
Shi XJ; Geng F; Jiao Z; Cui XY; Qiu XY; Zhong MK
J Clin Pharm Ther; 2011 Oct; 36(5):614-24. PubMed ID: 21916909
[TBL] [Abstract][Full Text] [Related]
10. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals.
Galteau MM; Shamsa F
Eur J Clin Pharmacol; 2003 Dec; 59(10):713-33. PubMed ID: 14605790
[TBL] [Abstract][Full Text] [Related]
11. Midazolam and cortisol metabolism before and after CYP3A induction in humans.
Eeckhoudt SL; Desager JP; Robert AR; Leclercq I; Verbeeck RK; Horsmans Y
Int J Clin Pharmacol Ther; 2001 Jul; 39(7):293-9. PubMed ID: 11471773
[TBL] [Abstract][Full Text] [Related]
12. The influence of taurine and L-carnitine on 6 β-hydroxycortisol/cortisol ratio in human urine of healthy volunteers.
Makhova AA; Shikh EV; Bulko TV; Sizova ZM; Shumyantseva VV
Drug Metab Pers Ther; 2019 Oct; 34(3):. PubMed ID: 31603853
[TBL] [Abstract][Full Text] [Related]
13. Sensitive and simultaneous quantitation of 6β-hydroxycortisol and cortisol in human plasma by LC-MS/MS coupled with stable isotope dilution method.
Hirano R; Yokokawa A; Furuta T; Shibasaki H
J Mass Spectrom; 2018 Aug; 53(8):665-674. PubMed ID: 29766610
[TBL] [Abstract][Full Text] [Related]
14. Interindividual and intraindividual variability of the urinary 6beta-Hydroxycortisol/Cortisol ratio in Chinese subjects: implications of its use for evaluating CYP3A activity.
Yin OQ; Shi X; Tomlinson B; Chow MS
J Clin Pharmacol; 2004 Dec; 44(12):1412-7. PubMed ID: 15545313
[TBL] [Abstract][Full Text] [Related]
15. A background subtraction approach for determination of endogenous cortisol and 6β-hydroxycortisol in urine by UPLC-MS/MS with application in a within-day variability study in HIV-infected pregnant women.
Benzi JRL; Moreira FL; Marques MP; Duarte G; Suarez-Kurtz G; Lanchote VL
J Chromatogr B Analyt Technol Biomed Life Sci; 2020 May; 1144():122074. PubMed ID: 32247187
[TBL] [Abstract][Full Text] [Related]
16. Impact of the Selective Orexin-1 Receptor Antagonist ACT-539313 on the Pharmacokinetics of the CYP3A Probe Drug Midazolam in Healthy Male Subjects.
Berger B; Kaufmann P; Koch A; Dingemanse J
J Clin Pharmacol; 2020 Jul; 60(7):931-941. PubMed ID: 32035014
[TBL] [Abstract][Full Text] [Related]
17. Changes in urinary 6beta-hydroxycortisol/cortisol ratio after birth in human neonates.
Nakamura H; Hirai M; Ohmori S; Ohsone Y; Obonai T; Sugita K; Niimi H; Kitada M
Eur J Clin Pharmacol; 1998 Jan; 53(5):343-6. PubMed ID: 9516034
[TBL] [Abstract][Full Text] [Related]
18. Genotype-phenotype variability in human CYP3A locus in Nepalese people residing in Bangladesh.
Hassan R; Ameen SS; Al Maruf A; Nandini A; Tabin H; Ahmed MU; Islam MS; Bin Sayeed MS; Hasnat A
Int J Clin Pharmacol Ther; 2013 Mar; 51(3):207-14. PubMed ID: 23320986
[TBL] [Abstract][Full Text] [Related]
19. Effect of CYP3A4 and CYP3A5 Genetic Polymorphisms on the Pharmacokinetics of Sirolimus in Healthy Chinese Volunteers.
Zhang J; Dai Y; Liu Z; Zhang M; Li C; Chen D; Song H
Ther Drug Monit; 2017 Aug; 39(4):406-411. PubMed ID: 28700521
[TBL] [Abstract][Full Text] [Related]
20. Dose-dependent inhibition of CYP3A activity by clarithromycin during Helicobacter pylori eradication therapy assessed by changes in plasma lansoprazole levels and partial cortisol clearance to 6beta-hydroxycortisol.
Ushiama H; Echizen H; Nachi S; Ohnishi A
Clin Pharmacol Ther; 2002 Jul; 72(1):33-43. PubMed ID: 12152002
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
